Financial Data and Key Metrics Changes - Total revenue for 2024 increased by 21%, with a core EPS growth of 19% [3][19] - Core operating expenses rose by 14%, indicating effective cost management relative to revenue growth [3][21] - Product sales grew by 19% for the full year, driven by strong demand across regions [19] Business Line Data and Key Metrics Changes - Oncology revenues reached $22.4 billion, a 24% increase, with Tagrisso surpassing $6.5 billion in sales [34] - BioPharmaceuticals revenue grew by 21% to $21.9 billion, with respiratory and immunology products showing strong performance [56] - Rare disease revenue increased by 16% to $8.8 billion, driven by demand and new market launches [74] Market Data and Key Metrics Changes - China revenue grew by 11% overall in 2024, despite a 3% decline in Q4 due to hospital ordering dynamics [10][11] - Emerging markets saw a growth of 22%, highlighting significant unmet medical needs [12] - The inhaled market in China experienced a slowdown, with Q4 growth at 9% compared to 23% in Q3 [105] Company Strategy and Development Direction - The company aims to deliver 20 new medicines by 2030, with eight already approved [5][87] - Investments are being made in manufacturing capabilities and transformative technologies to support long-term growth [32][86] - The company is focused on achieving $80 billion in total revenue by 2030, with ongoing high-value trial readouts expected to drive growth [84][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential in emerging markets, particularly in China, despite current headwinds [14][108] - The company anticipates continued strong performance in 2025, with total revenue expected to increase by a high single-digit percentage [27] - Management acknowledged challenges from VBP inclusion in China but remains optimistic about overall portfolio growth [108] Other Important Information - The company is facing ongoing investigations in China related to unpaid importation taxes, with potential fines if found liable [6][10] - Significant investments are being made in next-generation manufacturing capabilities and technology to support future growth [32][30] Q&A Session Summary Question: Insights on China revenue dynamics - The revenue in Q4 declined by 3%, primarily due to hospital inventory management and a mild winter affecting respiratory product demand [10][11][102] - Management noted that the respiratory portfolio is expected to perform better as flu infections rise in early 2025 [104][108] Question: Guidance assumptions for China - The guidance for 2025 considers potential declines in China due to VBP inclusion for certain products, but overall growth is still anticipated [92][108] Question: Investigations and potential fines - The company disclosed a potential liability related to investigations, with fines possibly ranging from 1 to 5 times the amount of avoided import duties [95][96]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

Full Year and Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025 Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statemen ...

For the quarter ended December 2024, Astrazeneca (AZN) reported revenue of $14.89 billion, up 23.8% over the same period last year. EPS came in at $1.05, compared to $0.73 in the year-ago quarter.The reported revenue represents a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion. With the consensus EPS estimate being $1.07, the EPS surprise was -1.87%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=127264&from=4 CLASS PERIOD: February 23, 2022 to ...

Core Viewpoint - AstraZeneca PLC is under investigation for potential securities fraud and unlawful business practices, with implications for its senior executives [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca, focusing on possible securities fraud or unlawful business practices by the company and its executives [1]. - A fraud investigation into AstraZeneca has expanded to include several Chinese government agencies, implicating numerous senior executives [2]. Group 2: Market Reaction - Following the news of the fraud investigation, AstraZeneca's American depositary receipt (ADR) price dropped by $5.16, or 7.22%, closing at $66.27 per ADR on November 5, 2024 [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Johnson & Johnson (JNJ) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the subcutaneous (SC) formulation of Rybrevant (amivantamab) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutation. The C ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=126295&from=3 CLASS PERIOD: February 23, ...